Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Ozguroglu · SciRah

Researcher profile · Semantic Scholar

M. Ozguroglu

Share profile

M. Ozguroglu — researcher profile on SciRah

h-index: 25
Works: 201
Citations: 6,711

Most-cited papers

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge +496 more
2017The Lancet Oncology512 citations
Semantic Scholar
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
D. Spigel, F. Marinis, G. Giaccone, N. Reinmuth +16 more
2019Annals of Oncology140 citations Open access
Semantic Scholar
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
D. Spigel, C. Faivre-Finn, J. Gray, D. Vicente +16 more
202186 citations
Semantic Scholar
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
A. Alva, T. Csőszi, M. Ozguroglu, N. Matsubara +16 more
202063 citations Open access
Semantic Scholar
PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
L. Paz-Ares, J. Goldman, M. Garassino, M. Dvorkin +16 more
2019Annals of Oncology50 citations Open access
Semantic Scholar
Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
M. Moehler, M. Dvorkin, M. Ozguroglu, M. Ryu +16 more
202047 citations
Semantic Scholar
LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
C. Faivre-Finn, D. Vicente, T. Kurata, D. Planchard +16 more
202036 citations Open access
Semantic Scholar
MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Ozguroglu +11 more
2018Journal of Thoracic Oncology36 citations Open access
Semantic Scholar
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
J. Goldman, M. Garassino, Yuh-Min Chen, N. Reinmuth +16 more
202030 citations Open access
Semantic Scholar
Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.
J. Chao, C. Fuchs, K. Shitara, J. Tabernero +16 more
202027 citations
Semantic Scholar
KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer.
K. Shitara, M. Ozguroglu, Yongju Bang, M. Di Bartolomeo +16 more
2018Annals of Oncology24 citations Open access
Semantic Scholar
Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
A. Angelergues, E. Efstathiou, R. Gyftaki, P. Wysocki +17 more
2018Clinical Genitourinary Cancer23 citations
Semantic Scholar
Three-year overall survival update from the PACIFIC trial.
J. Gray, A. Villegas, D. Daniel, D. Vicente +16 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta +19 more
2019Journal of Thoracic Oncology19 citations Open access
Semantic Scholar
LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
K. Fizazi, N. Tran, L. Fein, N. Matsubara +11 more
201718 citations
Semantic Scholar
Three-year overall survival update from the PACIFIC trial
Y.-L. Wu, J. Gray, A. Villegas, D. Daniel +16 more
2019Annals of Oncology16 citations Open access
Semantic Scholar
BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC)
M. Royce, C. Villanueva, M. Ozguroglu, T. Bachelot +10 more
201615 citations Open access
Semantic Scholar
Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).
N. Agarwal, S. Chowdhury, A. Bjartell, B. Chung +12 more
202014 citations
Semantic Scholar
Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
J. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Ozguroglu +11 more
2019Annals of Oncology14 citations Open access
Semantic Scholar
Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
K. Chi, S. Chowdhury, A. Bjartell, B. Chung +16 more
202113 citations
Semantic Scholar
1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.
T. Powles, T. Csőszi, M. Ozguroglu, N. Matsubara +16 more
202113 citations
Semantic Scholar
610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
J. de Bono, J. Mateo, K. Fizazi, F. Saad +16 more
2020Annals of Oncology13 citations Open access
Semantic Scholar
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
K. Fizazi, N. Tran, L. Fein, N. Matsubara +10 more
2019Journal of Clinical Oncology13 citations
Semantic Scholar
Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
C. Fuchs, M. Ozguroglu, Y. Bang, M. Di Bartolomeo +16 more
201813 citations
Semantic Scholar
Prognostic Value of Baseline Neutrophil‐to‐Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First‐line Chemotherapy: A Large Multicenter Study
M. Auvray, R. Elaidi, M. Ozguroglu, S. Guven +9 more
2017Clinical Genitourinary Cancer13 citations
Semantic Scholar
LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
L. Paz-Ares, Yuh-Min Chen, N. Reinmuth, K. Hotta +16 more
2021Annals of Oncology12 citations Open access
Semantic Scholar
1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
A. Armstrong, F. Saad, A. Thiery-Vuillemin, M. Oya +14 more
2022Annals of Oncology11 citations Open access
Semantic Scholar
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
B. Levy, L. Paz-Ares, J. Bennouna, E. Felip +16 more
2019Clinical Lung Cancer11 citations Open access
Semantic Scholar
JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).
M. Moehler, M. Ryu, Keun-Wook Lee, H. Coşkun +15 more
201811 citations
Semantic Scholar
PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
J. de Bono, K. Fizazi, F. Saad, N. Shore +16 more
20209 citations
Semantic Scholar
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
D. Planchard, B. Cho, J. Gray, L. Paz-Ares +14 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
R. Herbst, F. de Marinis, G. Giaccone, N. Reinmuth +16 more
20199 citations Open access
Semantic Scholar
Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.
F. Cardoso, C. Villanueva, M. Royce, F. M. Cruz +13 more
20179 citations
Semantic Scholar
O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
H. Yoon, C. Fuchs, M. Ozguroglu, Y. Bang +18 more
20208 citations Open access
Semantic Scholar
Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer.
Kiyoko Kato, M. Shah, P. Enzinger, J. Bennouna +12 more
2018Annals of Oncology8 citations Open access
Semantic Scholar
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
M. Ozguroglu, A. Sezer, S. Kılıçkap, M. Gumus +16 more
20217 citations
Semantic Scholar
O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC
R. Herbst, F. Marinis, G. Giaccone, N. Reinmuth +16 more
2020Journal of Immunotherapy for Cancer7 citations Open access
Semantic Scholar
Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.
K. Shitara, T. Doi, H. Hosaka, P. Thuss-Patience +15 more
2019Journal of Clinical Oncology7 citations
Semantic Scholar
Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.
K. Fizazi, S. Feyerabend, N. Matsubara, M. Ozguroglu +11 more
20187 citations
Semantic Scholar
The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
K. Chi, A. Merseburger, M. Ozguroglu, S. Chowdhury +16 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
M. Ozguroglu, B. Levy, H. Horinouchi, J. Yu +5 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
N. Reinmuth, M. Garassino, D. Trukhin, M. Hochmair +12 more
20216 citations Open access
Semantic Scholar
LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
L. Paz-Ares, A. Villegas, D. Daniel, D. Baz +16 more
20176 citations Open access
Semantic Scholar
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
K. Chi, N. Agarwal, A. Bjartell, B. Chung +16 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
R. Morales-Barrera, T. Powles, M. Ozguroglu, T. Csőszi +16 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
S. Kılıçkap, A. Sezer, M. Gumus, I. Bondarenko +20 more
20214 citations
Semantic Scholar
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.
M. Ozguroglu, S. Chowdhury, A. Bjartell, H. Uemura +9 more
20204 citations
Semantic Scholar
A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
C. Pauli, T. Bochtler, L. Mileshkin, G. Baciarello +12 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC
R. Hui, M. Ozguroglu, D. Daniel, D. Baz +12 more
20174 citations Open access
Semantic Scholar
Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.
Y. Loriot, A. Alva, T. Csőszi, M. Ozguroglu +16 more
20213 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Paz-Ares×12
Invite
L. Paz-Ares — researcher profile on SciRah
R. Hui×9
Invite
R. Hui — researcher profile on SciRah
K. Chi×9
Invite
K. Chi — researcher profile on SciRah
D. Spigel×7
Invite
D. Spigel — researcher profile on SciRah

×7

Invite

D. Daniel — researcher profile on SciRah

Invite

P. Dennis — researcher profile on SciRah

N. Matsubara×7

Invite

N. Matsubara — researcher profile on SciRah

C. Faivre-Finn×6

Invite

C. Faivre-Finn — researcher profile on SciRah

Invite

J. Gray — researcher profile on SciRah

D. Planchard×6

Invite

D. Planchard — researcher profile on SciRah

J. Vansteenkiste×6

Invite

J. Vansteenkiste — researcher profile on SciRah

Invite

N. Reinmuth — researcher profile on SciRah